Oppenheimer Holdings, Inc. reissued their buy rating on shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in a report published on Sunday. The firm currently has a $25.00 price target on the biopharmaceutical company’s stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q3 2018 earnings at $0.00 EPS and Q4 2018 earnings at $0.04 EPS.

Several other research firms have also weighed in on VNDA. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a strong-buy rating to a hold rating in a research report on Thursday, October 5th. Piper Jaffray Companies increased their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an overweight rating in a research report on Thursday, September 14th. Jefferies Group LLC restated a buy rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $21.50.

Vanda Pharmaceuticals (VNDA) opened at $12.95 on Friday. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The company had revenue of $41.30 million during the quarter, compared to analyst estimates of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.01) earnings per share. research analysts forecast that Vanda Pharmaceuticals will post -0.39 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Earns Buy Rating from Oppenheimer Holdings, Inc.” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/11/15/vanda-pharmaceuticals-inc-vnda-earns-buy-rating-from-oppenheimer-holdings-inc.html.

A number of large investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC boosted its position in Vanda Pharmaceuticals by 221.3% during the third quarter. Cubist Systematic Strategies LLC now owns 25,387 shares of the biopharmaceutical company’s stock worth $454,000 after purchasing an additional 17,485 shares during the period. University of Notre Dame DU Lac bought a new position in Vanda Pharmaceuticals during the third quarter worth about $2,824,000. Schwab Charles Investment Management Inc. boosted its position in Vanda Pharmaceuticals by 2.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 472,516 shares of the biopharmaceutical company’s stock worth $8,459,000 after purchasing an additional 11,647 shares during the period. Wells Fargo & Company MN boosted its position in Vanda Pharmaceuticals by 112.2% during the third quarter. Wells Fargo & Company MN now owns 151,693 shares of the biopharmaceutical company’s stock worth $2,715,000 after purchasing an additional 80,209 shares during the period. Finally, Cadence Capital Management LLC bought a new position in Vanda Pharmaceuticals during the third quarter worth about $1,121,000. Hedge funds and other institutional investors own 87.28% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.